Literature DB >> 2919718

Pathologic features of prognostic significance in adrenocortical carcinoma.

L M Weiss1, L J Medeiros, A L Vickery.   

Abstract

There are currently no well-established pathologic prognostic factors helpful in distinguishing low versus high grade adrenocortical carcinomas. The effect of 11 pathologic parameters on survival was investigated in 42 cases of adrenocortical carcinoma. Only one variable, mitotic rate, had a strong statistical association with patient outcome. The 21 patients with carcinomas with greater than 20 mitoses per 50 high power fields (hpf) had a median survival of 14 months, whereas the 21 patients with carcinomas with less than or equal to 20 mitoses had a median survival of 58 months (p less than 0.02). The presence of atypical mitoses, capsular invasion, tumor weight greater than 250 g, and size greater than 10 cm each showed a marginal statistical association with poor survival (p less than 0.06), whereas other features assessed, such as nuclear grade, presence of necrosis or of venous or sinusoidal invasion, character of the tumor cell cytoplasm, or architectural pattern, showed no statistical significance in predicting survival. It is proposed that adrenal cortical carcinomas with greater than 20 mitoses be designated high grade, whereas tumors with less than or equal to 20 mitoses be designated low grade.

Entities:  

Mesh:

Year:  1989        PMID: 2919718     DOI: 10.1097/00000478-198903000-00004

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  175 in total

Review 1.  Current perspective in the diagnosis and treatment of adrenocortical carcinoma.

Authors:  D E Schteingart
Journal:  Rev Endocr Metab Disord       Date:  2001-08       Impact factor: 6.514

Review 2.  FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma.

Authors:  Désirée Deandreis; Sophie Leboulleux; Caroline Caramella; Martin Schlumberger; Eric Baudin
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

3.  Oncocytome de la surrénale : Étude de cas.

Authors:  Chiraz Chaari; Abdelmajid Khabir; Hela Mnif; Mohamed Abid; Mohamed Nabil Mhiri; Tahia Sellami Boudawara
Journal:  Can Urol Assoc J       Date:  2011-10       Impact factor: 1.862

Review 4.  Aldosterone-secreting adrenal cortical carcinoma. A case report and review of the literature.

Authors:  Adrienne Carruth Griffin; Rachel Kelz; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

5.  Genomic and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin mutations as potential prognostic biomarker.

Authors:  Alexandra E Kovach; Carmelo Nucera; Quynh T Lam; Ahnthu Nguyen; Dora Dias-Santagata; Peter M Sadow
Journal:  Discoveries (Craiova)       Date:  2015 Apr-Jun

6.  Adrenal cortical diseases: international case conference.

Authors:  Hironobu Sasano; Takashi Suzuki; Junji Irie; Kioko Kawai; Motohiko Aiba; Anne Marie McNicol; Hiroshi Takami
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 7.  A case of normoreninemic aldosterone-producing adenoma associated with chronic renal failure: case report and literature review.

Authors:  Hiroyuki Koshiyama; Takeshi Fujisawa; Naomitsu Kuwamura; Yoshio Nakamura; Hiroshi Kanamori; Emi Oida; Akira Hara; Takashi Suzuki; Hironobu Sasano
Journal:  Endocrine       Date:  2003-08       Impact factor: 3.633

Review 8.  [Adrenocortical tumours].

Authors:  W Saeger
Journal:  Pathologe       Date:  2003-05-06       Impact factor: 1.011

Review 9.  Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms.

Authors:  Ozgur Mete; Sylvia L Asa; Thomas J Giordano; Mauro Papotti; Hironobu Sasano; Marco Volante
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

10.  Giant non-functional adrenal adenoma: A case report.

Authors:  Baozhong Li; Qingqu Guo; Haijun Yang; Jianyun Guan
Journal:  Oncol Lett       Date:  2012-10-19       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.